Dapagliflozin is well tolerated in patients with COVID-19, regardless of eGFR – Consumer Health News

FRIDAY, April 29, 2022 (HealthDay News) — The effects of dapagliflozin are similar for hospitalized patients with COVID-19 with estimated glomerular filtration rate (eGFR) 2according to a study published online April 28 in the Clinical Journal of the American Society of Nephrology.

Hiddo JL Heerspink, Ph.D., Pharm.D., of University Medical Center Groningen in the Netherlands, and colleagues conducted a secondary analysis of the Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19 ), which 1,250 hospitalized patients with COVID-19 with cardiometabolic risk factors were randomly assigned to dapagliflozin or placebo. Dual primary outcomes (time to onset or worsening of organ dysfunction or death and a hierarchical composite endpoint of recovery) and secondary primary outcomes for kidney were been evaluated in individuals whose baseline eGFR was 2.

The researchers found that across all eGFR subgroups, the effect of dapagliflozin compared to placebo was consistent on the primary prevention outcome (hazard ratio, 0.80; 95% confidence interval, 0.58 to 1.10), primary recovery outcome (win ratio, 1.09; 95% confidence interval, 0.97 to 1.22), and composite kidney outcome (relative risk, 0 .74; 95% confidence interval, 0.50 to 1.07; P for interaction, 0.98, 0.67 and 0.44, respectively). The effects of dapagliflozin on acute kidney injury were also similar for people with an eGFR 2 (relative risk, 0.71; 95% confidence interval, 0.29 to 1.77) and ≥ 60 mL/min per 1.73 m2 (relative risk, 0.69; 95% confidence interval, 0.37 to 1.29). In patients with an eGFR 2dapagliflozin was well tolerated.

“These new data from DARE-19 reinforce the safety of dapagliflozin in critically ill patients hospitalized with COVID-19, even in those with reduced kidney function who are at particularly high risk of acute kidney injury,” Heerspink said. in a press release.

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which manufactures dapagliflozin and funded the study.

Summary/Full text

Editorial

Comments are closed.